journal article·2020-11Open access

Oncogenic State and Cell Identity Combinatorially Dictate the Susceptibility of Cells within Glioma Development Hierarchy to IGF1R Targeting

Anhao Tian, Bo Kang, Baizhou Li, Biying Qiu, Wenhong Jiang, Fangjie Shao, Qingqing Gao, Rui Liu, Chengwei Cai, Rui Jing, Wei Wang, Pengxiang Chen, Qinghui Liang, Lili Bao, Jianghong Man, Yan Wang, Yu Shi, Jin Li, Minmin Yang, Lisha Wang, Jianmin Zhang, Simon Hippenmeyer, Junming Zhu, Xiuwu Bian, Ying‐Jie Wang, Chong Liu

Advanced Science· Volume 7· Issue 21

Abstract

Abstract Glioblastoma is the most malignant cancer in the brain and currently incurable. It is urgent to identify effective targets for this lethal disease. Inhibition of such targets should suppress the growth of cancer cells and, ideally also precancerous cells for early prevention, but minimally affect their normal counterparts. Using genetic mouse models with neural stem cells (NSCs) or oligodendrocyte precursor cells (OPCs) as the cells‐of‐origin/mutation, it is shown that the susceptibility of cells within the development hierarchy of glioma to the knockout of insulin‐like growth factor I receptor (IGF1R) is determined not only by their oncogenic states, but also by their cell identities/states. Knockout of IGF1R selectively disrupts the growth of mutant and transformed, but not normal OPCs, or NSCs. The desirable outcome of IGF1R knockout on cell growth requires the mutant cells to commit to the OPC identity regardless of its development hierarchical status. At the molecular level, oncogenic mutations reprogram the cellular network of OPCs and force them to depend more on IGF1R for their growth. A new‐generation brain‐penetrable, orally available IGF1R inhibitor harnessing tumor OPCs in the brain is also developed. The findings reveal the cellular window of IGF1R targeting and establish IGF1R as an effective target for the prevention and treatment of glioblastoma.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Neurogenesis and neuroplasticity mechanisms · FOXO transcription factor regulation · Epigenetics and DNA Methylation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Neurosurgery of the Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou 310058 China

Department of Pathology and Pathophysiology Zhejiang University School of Medicine Hangzhou 310058 China

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou 310058 China

Department of Pathology of the Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou 310058 China

College of Basic Medical Science Inner Mongolia Medical University Hohhot 010059 China

State Key Laboratory of Proteomics Institute of Basic Medical Sciences National Center of Biomedical Analysis Beijing 100850 China

Department of Pathology Institute of Pathology and Southwest Cancer Center Southwest Hospital Third Military Medical University Chongqing 400038 China

PharmaBlock Sciences (Nanjing), Inc. Nanjing 210032 China

Institute of Science and Technology Austria Am Campus 1 Klosterneuburg 3400 Austria

School of Brain Science and Brain Medicine NHC and CAMS Key Laboratory of Medical Neurobiology Zhejiang University School of Medicine Hangzhou 310058 China

Funding

National Basic Research Program of China · National Key Research and Development Program of China Stem Cell and Translational Research · National Natural Science Foundation of China · Fundamental Research Funds for the Central Universities · European Research Council

References (55)

Show source-provided references
1. 10.1007/s00401-007-0243-410.1007/s00401-007-0243-4 ↗
2. 10.1016/j.ccr.2011.03.00410.1016/j.ccr.2011.03.004 ↗
3. 10.1126/scitranslmed.aah681610.1126/scitranslmed.aah6816 ↗
4. 10.1016/j.ccell.2015.09.00710.1016/j.ccell.2015.09.007 ↗
5. 10.1038/s41586-019-0993-x10.1038/s41586-019-0993-x ↗
6. 10.1038/nrn249510.1038/nrn2495 ↗
7. 10.1016/j.cell.2011.06.01410.1016/j.cell.2011.06.014 ↗
8. 10.1073/pnas.141438911110.1073/pnas.1414389111 ↗
9. 10.1016/j.ccell.2016.03.02710.1016/j.ccell.2016.03.027 ↗
10. 10.1523/JNEUROSCI.0514-06.200610.1523/JNEUROSCI.0514-06.2006 ↗
11. 10.1016/j.ccr.2010.10.03310.1016/j.ccr.2010.10.033 ↗
12. 10.1038/onc.2009.7610.1038/onc.2009.76 ↗
13. 10.1016/j.ccell.2017.03.01110.1016/j.ccell.2017.03.011 ↗
14. 10.1038/nrc321510.1038/nrc3215 ↗
15. 10.1093/neuonc/nov09610.1093/neuonc/nov096 ↗
16. 10.1126/science.aad301810.1126/science.aad3018 ↗
17. 10.1038/bjc.2015.24210.1038/bjc.2015.242 ↗
18. 10.1016/j.neuron.2011.01.02310.1016/j.neuron.2011.01.023 ↗
19. Resnicoff M. · J. Exp. Ther. Oncol. · 1996 · 1 · 385
20. 10.1093/neuonc/nop00810.1093/neuonc/nop008 ↗
21. 10.1093/neuonc/nou34410.1093/neuonc/nou344 ↗
22. 10.1073/pnas.061127110410.1073/pnas.0611271104 ↗
23. 10.18632/oncotarget.2066210.18632/oncotarget.20662 ↗
24. 10.1523/JNEUROSCI.1860-14.201410.1523/JNEUROSCI.1860-14.2014 ↗
25. 10.1093/neuonc/now06210.1093/neuonc/now062 ↗
26. 10.1016/j.cell.2019.06.02410.1016/j.cell.2019.06.024 ↗
27. 10.1016/j.neuron.2007.01.00910.1016/j.neuron.2007.01.009 ↗
28. 10.1016/j.ccell.2018.03.02010.1016/j.ccell.2018.03.020 ↗
29. 10.1007/s11060-017-2547-010.1007/s11060-017-2547-0 ↗
30. 10.1038/nm.441510.1038/nm.4415 ↗
31. 10.1126/science.aao475010.1126/science.aao4750 ↗
32. 10.1038/nature2012310.1038/nature20123 ↗
33. 10.1210/er.2006-000110.1210/er.2006-0001 ↗
34. 10.1016/j.cell.2005.02.01210.1016/j.cell.2005.02.012 ↗
35. 10.1523/JNEUROSCI.1299-06.200610.1523/JNEUROSCI.1299-06.2006 ↗
36. 10.1038/nn.415910.1038/nn.4159 ↗
37. 10.1016/j.cell.2019.08.01310.1016/j.cell.2019.08.013 ↗
38. 10.1111/acel.1236510.1111/acel.12365 ↗
39. 10.1158/0008-5472.CAN-10-005210.1158/0008-5472.CAN-10-0052 ↗
40. 10.1371/journal.pone.000034010.1371/journal.pone.0000340 ↗
41. 10.3109/0284186X.2015.104929010.3109/0284186X.2015.1049290 ↗
42. 10.1038/s41467-018-03219-710.1038/s41467-018-03219-7 ↗
43. 10.1038/s41467-019-12564-010.1038/s41467-019-12564-0 ↗
44. 10.1158/2159-8290.CD-19-032910.1158/2159-8290.CD-19-0329 ↗
45. 10.1073/pnas.96.13.732410.1073/pnas.96.13.7324 ↗
46. 10.1016/j.cell.2014.03.05810.1016/j.cell.2014.03.058 ↗
47. 10.3109/0284186X.2010.49937010.3109/0284186X.2010.499370 ↗
48. 10.1158/1078-0432.CCR-14-251810.1158/1078-0432.CCR-14-2518 ↗
49. 10.1158/1078-0432.CCR-14-026510.1158/1078-0432.CCR-14-0265 ↗
50. 10.1016/j.ctrv.2014.07.00410.1016/j.ctrv.2014.07.004 ↗
51. 10.1523/JNEUROSCI.2572-06.200610.1523/JNEUROSCI.2572-06.2006 ↗
52. 10.1016/j.cell.2019.05.03110.1016/j.cell.2019.05.031 ↗
53. 10.1038/nbt.285910.1038/nbt.2859 ↗
54. 10.1016/j.cell.2014.10.02710.1016/j.cell.2014.10.027 ↗
55. 10.1016/j.cell.2011.05.02410.1016/j.cell.2011.05.024 ↗